- High Fusion (FUZN) subsidiary, Neural Therapeutics has announced plans to complete a non-brokered private placement of units for proceeds of up to $750,000
- Units will be comprised of one common share of Neural Therapeutics and one-half of one common share purchase warrant
- Net proceeds from the offering will be used for research and development and general working capital
- High Fusion is focused on developing and manufacturing branded products in the cannabis industry
- Neural Therapeutics, a wholly-owned subsidiary of High Fusion, is an ethnobotanical drug discovery and development company
- High Fusion Inc. (FUZN) opened trading at C$0.16 per share
High Fusion (FUZN) subsidiary, Neural Therapeutics has announced a non-brokered private placement of units for proceeds of up to $750,000.
Units will be comprised of one common share of Neural Therapeutics and one-half of one common share purchase warrant. Each whole warrant will be exercisable into one Neural Share at an exercise price of $0.10.
Net proceeds from the offering will be used for research and development and general working capital.
High Fusion is focused on developing and manufacturing branded products in the cannabis industry with a specific focus on flower, pro-rolls, vapes, edibles and oil extracts for medical and adult recreational use. The company operates in California, Colorado and Oregon.
High Fusion has manufacturing, retail and grow operations in California through its acquisition of OutCo and operates oil extraction and edible manufacturing facilities in Colorado and Oregon.
Neural Therapeutics, a wholly-owned subsidiary of High Fusion, is an ethnobotanical drug discovery and development company.
High Fusion Inc. (FUZN) opened trading at C$0.16 per share.
